This post was originally published on this site Combining Ibrance (palbociclib), a treatment for advanced breast cancer, with the lung cancer medicine crizotinib is more effective against human cancer cells in the laboratory than either drug alone, scientists have found. The researchers say the findings suggest the combination could be used to overcome treatment resistance in some…
This post was originally published on this site The small molecule inhibitor SM07883, being developed by Samumed, can effectively prevent tau protein toxic accumulation, and tau-mediated neuroinflammation in mice, data from preclinical studies show. As tau-associated mechanisms are implicated in Alzheimer’s disease, these findings suggest that SM07883 may represent a new strategy for the treatment…
This post was originally published on this site CURE Media Group has introduced a video discussion series on topics of concern to prostate cancer patients, including cardiovascular risk management and androgen deprivation therapy (ADT). Called “ADT in Prostate Cancer: Managing Cardiovascular Risk,” the nine-episode series features Andy Rochester, a prostate cancer survivor, discussing his experiences with Susan F.…
This post was originally published on this site A new collaborative project seeks to help ovarian cancer programs better understand and remove impediments to optimal care for patients with advanced epithelial disease. Called “Barriers to Quality Care in Ovarian Cancer,” the effort will be led by the Association of Community Cancer Centers (ACCC), along with AstraZeneca…
This post was originally published on this site Adding Darzalex (daratumumab) to a treatment combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone increased the proportion of newly diagnosed patients with multiple myeloma showing complete cancer disappearance, according to top-line results of a Phase 2 clinical trial. The open-label GRIFFIN study (NCT02874742) includes 223 patients eligible for high-dose chemotherapy…
This post was originally published on this site NantKwest is launching the first-in-human Phase 1 clinical trial assessing the effects of its investigational CD19 t-haNK cell therapy in people with locally advanced B-cell lymphoma. The trial follows the U.S. Food and Drug Administration‘s approval of NantKwest’s investigational new drug (IND) application for the therapy. Natural…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved three clinical studies testing PrimeVax Immuno-Oncology’s investigational approach using dendritic cells and dengue virus for cancer treatment. The investigational new drug (IND) application is for patients with melanoma (skin cancer) who have failed prior immune checkpoint inhibitors. Hospital…
This post was originally published on this site The bad news? It was cancer. The good news? It was in the early stages, a baby tumor at 1.5 cm. It’s hard to believe something so small has such a big impact. My friend Lauren went to a routine mammogram and was surprised when she heard…
This post was originally published on this site MSN Labs, the parent company of Novadoz Pharmaceuticals, is launching a generic version of Janssen Pharmaceuticals’ approved therapy Zytiga (abiraterone acetate) in the U.S. market. Following its approval by the U.S. Food and Drug Administration (FDA), the generic abiraterone acetate 250mg tablets will be available for the…
This post was originally published on this site According to a new study comparing older and younger sarcoidosis patients, elderly people with sarcoidosis tend to have more severe disease and worse clinical outcomes. The study, “Elderly sarcoidosis: A comparative study from a 42-year single-centre experience,” was published in the journal Respiratory Medicine. Sarcoidosis usually presents in…
